Durgesh Bhandary
Overview
Explore the profile of Durgesh Bhandary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olufade T, Atreja N, Bhalla N, Venditto J, Bhandary D, Chafekar K, et al.
Cardiol Ther
. 2021 Aug;
10(2):515-529.
PMID: 34389941
Introduction: Prescribing patterns and suboptimal adherence present methodological challenges for real-world head-to-head comparisons of ticagrelor and clopidogrel in intent-to-treat studies. The aim of this study was to compare ticagrelor and...
2.
Shah S, Liang L, Bhandary D, Johansson S, Smith E, Bhatt D, et al.
Stroke Vasc Neurol
. 2020 Nov;
6(2):314-318.
PMID: 33148542
Background: Long-term outcomes for Medicare beneficiaries hospitalised with transient ischaemic attack (TIA) and role of ABCD score in identifying high-risk individuals are not studied. Methods: We identified 40 825 Medicare...
3.
Bhandary D, Atreja N, Belletti D, Bhalla N, Khan N, Cobden D
Am J Manag Care
. 2020 Oct;
26(13 Suppl):S275-S286.
PMID: 33073970
Innovative value strategies for reimbursement of medications include value-based agreements (VBAs) between payers and pharmaceutical manufacturers, which have the potential to improve affordability and patient access to therapy, as well...
4.
Wang T, Kaltenbach L, Cannon C, Fonarow G, Choudhry N, Henry T, et al.
JAMA
. 2019 Jan;
321(1):44-55.
PMID: 30620370
Importance: Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial infarction (MI), and higher-potency P2Y12 inhibitors are underutilized. Cost is frequently cited...
5.
Horne B, Muhlestein J, Bhandary D, Hoetzer G, Khan N, Bair T, et al.
Open Heart
. 2018 Mar;
5(1):e000723.
PMID: 29531761
Objective: Post-myocardial infarction (MI) care is crucial to preventing recurrent major adverse cardiovascular events (MACE), but can be complicated to personalise. A tool is needed that effectively stratifies risk of...
6.
Wright E, Steinhubl S, Jones J, Barua P, Yan X, Van Loan R, et al.
Am J Manag Care
. 2017 May;
23(4):e106-e112.
PMID: 28554213
Objectives: Cardioprotective medications improve outcomes following acute coronary syndromes (ACS) but add to medication complexity. We set out to describe the use of these medications and quantify medication changes in...
7.
Page 2nd R, Ghushchyan V, Van Den Bos J, Gray T, Hoetzer G, Bhandary D, et al.
Vasc Health Risk Manag
. 2016 Feb;
12:13-21.
PMID: 26893568
Background: No studies have addressed the cost of inpatient mortality during an acute coronary syndrome (ACS) admission. Objective: Compare ACS-related length of stay (LOS), total admission cost, and total admission...